SREBF1 and hepatocellular carcinoma: Studies have shown that blocking the SREBP-1 pathway by inhibiting SREBP Cleavage Activating Protein (SCAP) can notably inhibit the progression of diethylnitrosamine-induced hepatocellular carcinoma (HCC) [15].